Characterizing a Conditional Transgenic Mouse Model of FSHD
FSHD 条件转基因小鼠模型的表征
基本信息
- 批准号:8845224
- 负责人:
- 金额:$ 8.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-05 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:4q35AcuteAffectAgeAnimal ModelAreaBiochemicalBreedingCellsChromosomesClinicalComplexD4Z4DataDevelopmentDiseaseDisease modelDoxycyclineEctopic ExpressionFacioscapulohumeral Muscular DystrophyGenesGeneticGoalsHealthHomeodomain ProteinsHumanImmunoblottingImmunohistochemistryIn Situ HybridizationIndividualLeadLengthModelingMolecularMolecular GeneticsMusMuscleMuscle WeaknessMuscle functionMuscular DystrophiesMyopathyNatureOralPathologyPhenotypePhysiologicalProteinsResearchSkeletal MuscleStagingSystemTestingTetanus Helper PeptideTetracyclinesTherapeuticTimeTissuesTransgenesTransgenic MiceTransgenic Modelage groupcytotoxicdisease mechanisms studydrinking waterhuman diseaseimprovedknock-downmRNA Expressionmouse modelprotein expressionresponsetooltransgene expression
项目摘要
DESCRIPTION (provided by applicant): Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscle disorder caused by complex genetic and molecular mechanisms. Recent discoveries improved our understanding of the genetic cause of FSHD and allowed us to focus our efforts on the aberrantly expressed DUX4 in FSHD. Knocking down the DUX4 protein in FSHD is an acute area of research since it is directly relevant to disease treatment. A suitable DUX4 model will provide a critical tool for such studies. Generating a suitable animal model for studying FSHD has been extremely challenging due to the cytotoxic nature of the DUX4 when it is ectopically expressed. To overcome this obstacle, we generated a tetracycline-repressible (tet-off) DUX4 transgenic mouse model. In this mouse model, the expression of DUX4 is controlled by oral doxycycline. The DUX4 transgene is suppressed when the mice receive oral doxycycline from their drinking water. Using this system, the expression of DUX4 can be induced at a desired time and the expression is restricted to skeletal muscles when the mouse is cross-bred with a mCK-tTA mouse line. In aim 1 of this application, we will characterize the phenotypes of the tet- repressible muscle-specific DUX4 transgenic mice (TRE-DUX4/mCK-tTA) and determine the effects of the duration of expression and the age of mice on the phenotypes. In aim 2, we will determine whether the phenotypes developed in response to the DUX4 expression is reversible. The main goal of this application is to characterize the mouse model and to determine whether the DUX4 model recapitulates the human disease at the physiological, histopathological and molecular level. If proven to be a suitable model for investigating FSHD mechanisms, testing therapeutic means or both, this DUX4 model will have a high impact to the field of FSHD research.
描述(由申请人提供):面肩肱型肌营养不良症(FSHD)是一种由复杂的遗传和分子机制引起的常染色体显性肌肉疾病。最近的发现提高了我们对FSHD遗传原因的理解,并使我们能够集中精力研究FSHD中异常表达的DUX 4。在FSHD中敲除DUX 4蛋白是一个急性研究领域,因为它与疾病治疗直接相关。合适的DUX 4模型将为此类研究提供关键工具。由于DUX 4在异位表达时的细胞毒性性质,产生用于研究FSHD的合适的动物模型极具挑战性。为了克服这一障碍,我们产生了四环素阻遏(tet-off)DUX 4转基因小鼠模型。在该小鼠模型中,DUX 4的表达由口服多西环素控制。当小鼠从饮用水中接受口服多西环素时,DUX 4转基因被抑制。使用该系统,当小鼠与mCK-tTA小鼠系杂交时,DUX 4的表达可以在期望的时间被诱导,并且表达被限制在骨骼肌。在本申请的目的1中,我们将表征泰特阻遏的肌肉特异性DUX 4转基因小鼠(TRE-DUX 4/mCK-tTA)的表型,并确定表达持续时间和小鼠年龄对表型的影响。在目标2中,我们将确定响应DUX 4表达而产生的表型是否可逆。本申请的主要目的是表征小鼠模型,并确定DUX 4模型是否在生理学、组织病理学和分子水平上重现人类疾病。如果被证明是研究FSHD机制,测试治疗手段或两者的合适模型,这种DUX 4模型将对FSHD研究领域产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YI-WEN CHEN其他文献
YI-WEN CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YI-WEN CHEN', 18)}}的其他基金
Investigating proteostasis in facioscapulohumeral muscular dystrophy
研究面肩肱型肌营养不良症的蛋白质稳态
- 批准号:
10430945 - 财政年份:2022
- 资助金额:
$ 8.39万 - 项目类别:
Investigating proteostasis in facioscapulohumeral muscular dystrophy
研究面肩肱型肌营养不良症的蛋白质稳态
- 批准号:
10652315 - 财政年份:2022
- 资助金额:
$ 8.39万 - 项目类别:
Investigating membrane repair capacity in facioscapulohumeral muscular dystrophy
研究面肩肱型肌营养不良症的膜修复能力
- 批准号:
10365948 - 财政年份:2021
- 资助金额:
$ 8.39万 - 项目类别:
A Long-read Sequencing Approach for Investigating Repeat Number and DNA Methylation of the D4Z4 Region
用于研究 D4Z4 区域重复数和 DNA 甲基化的长读长测序方法
- 批准号:
10093171 - 财政年份:2020
- 资助金额:
$ 8.39万 - 项目类别:
Molecular Pathphysiology of FSHD muscular dystrophy via genome-wide approaches
通过全基因组方法研究 FSHD 肌营养不良症的分子病理生理学
- 批准号:
8073308 - 财政年份:2010
- 资助金额:
$ 8.39万 - 项目类别:
Molecular Pathphysiology of FSHD muscular dystrophy via genome-wide approaches
通过全基因组方法研究 FSHD 肌营养不良症的分子病理生理学
- 批准号:
7817383 - 财政年份:2009
- 资助金额:
$ 8.39万 - 项目类别:
Molecular Pathphysiology of FSHD muscular dystrophy via genome-wide approaches
通过全基因组方法研究 FSHD 肌营养不良症的分子病理生理学
- 批准号:
7209944 - 财政年份:2007
- 资助金额:
$ 8.39万 - 项目类别:
Molecular Pathphysiology of FSHD muscular dystrophy via genome-wide approaches
通过全基因组方法研究 FSHD 肌营养不良症的分子病理生理学
- 批准号:
7569419 - 财政年份:2007
- 资助金额:
$ 8.39万 - 项目类别:
Molecular Pathphysiology of FSHD muscular dystrophy via genome-wide approaches
通过全基因组方法研究 FSHD 肌营养不良症的分子病理生理学
- 批准号:
7772306 - 财政年份:2007
- 资助金额:
$ 8.39万 - 项目类别:
Molecular Pathphysiology of FSHD muscular dystrophy via genome-wide approaches
通过全基因组方法研究 FSHD 肌营养不良症的分子病理生理学
- 批准号:
7383818 - 财政年份:2007
- 资助金额:
$ 8.39万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 8.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 8.39万 - 项目类别:
Operating Grants